Amgen notes AstraZeneca makes US biologics application for asthma drug

(Alliance News) - AstraZeneca PLC has made a biologics license application in the US for its ...

Alliance News 10 May, 2021 | 5:24PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - AstraZeneca PLC has made a biologics license application in the US for its tezepelumab asthma drug, partner Amgen Inc said on Monday.

The application follows data from a Phase 3 trial which showed the drug "demonstrated a statistically significant" reduction in asthma exacerbation rate compared to a placebo.

"Tezepelumab is the only biologic to consistently and significantly reduce AAER in a broad population of severe asthma patients irrespective of the baseline eosinophil counts across Phase 2 and Phase 3 clinical trials," Amgen said.

Amgen's Executive Vice President of Research & Development David Reese added: "This submission brings us one step closer to providing this potentially transformative treatment option to a broad population of severe asthma patients, across phenotypes and irrespective of biomarkers."

Astra's shares closed down 0.2% at 7,717.00 pence each in London on Monday. Amgen shares were 0.1% lower at USD254.02 each in New York on Monday afternoon.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 8,384.00 GBX 0.01
Amgen Inc 238.68 USD -0.86

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement